Roche
Neurology

Author Of 3 Presentations

Biomarkers and Bioinformatics Poster Presentation

P0081 - Exploring the usability and patient satisfaction of a virtual rehabilitation program in multiple sclerosis: The RehabVR study protocol (ID 210)

Speakers
Presentation Number
P0081
Presentation Topic
Biomarkers and Bioinformatics

Abstract

Background

Background: There is an association between motor and cognitive impairment in patients with multiple sclerosis (MS) over their disease course and strong evidence that physical therapy can prevent disability progression in these patients. Virtual reality (VR) has emerged as a promising treatment approach in rehabilitation for patients with MS due to its potential to increase patient motivation and rehabilitation adherence. However, there is a lack of studies about its safety, feasibility and effectiveness in MS patients.

Objectives

Objectives: The objective of this study protocol is to evaluate the feasibility, adherence, safety and effectiveness of a virtual reality rehabilitation (VRR) program in MS patients compared to a conventional rehabilitation (CR) program.

Methods

Methods: A randomized, prospective, open-label, controlled feasibility study will be conducted in a sample of 48 individuals diagnosed with MS. Participants will be allocated 2:1 to the VRR group (32) or CR group (16). Both groups will perform 8 in-hospital physical therapy sessions of 2 hours each, twice a week over 4 weeks. The VRR group will perform half of these sessions with a VRR tool. In addition, both groups will continue rehabilitation at home for 5 months. The VRR program was designed by a multidisciplinary group of healthcare professionals (neurologists, physiatrists, physiotherapists, neuropsychologists) according to a validated CR program. Feasibility will be assessed by the User Satisfaction Evaluation Questionnaire (USEQ). Secondary outcomes include adherence, disability, spasms and spasticity, balance, fatigue, activities of daily living, depression, anxiety, work status, cognition, demographic and clinical characteristics (in the VRR and CR groups), and safety (in the VRR group). Outcome measures will be assessed at baseline and at 1 and 6 months from the start of rehabilitation.

Results

Results: Due to the present comunication is a description of an ongoing study protocol there are stil not results to present.

Conclusions

Conclusions: A better understanding of long-term patient satisfaction with a VRR program specifically designed for MS patients would allow us to optimize the rehabilitation program and to collect valuable information for its implementation in the clinical practice. Additionally, the study will provide information on long-term adherence, changes in motor symptoms, cognitive function and patient-reported outcomes after the rehabilitation program. Altogether, the results from this study will help to gather valuable knowledge on the use of rehabilitation with a new VR tool in MS patients.

Collapse
Patient-Reported Outcomes and Quality of Life Poster Presentation

P1016 - Designing of a multicenter, non-interventional study to assess subjective disease perception in early-stage relapsing-remitting multiple sclerosis (ID 233)

Presentation Number
P1016
Presentation Topic
Patient-Reported Outcomes and Quality of Life

Abstract

Background

Relapsing-remitting multiple sclerosis (RRMS) has an uncertain prognosis. Patients´ subjective experience living the first few years after the diagnosis may impact their perception of the clinical course, well-being, and decision-making process.

Objectives

To assess the influence of the early-course of the RRMS on patients’ disease perception using a comprehensive standardized battery of patient-reported outcomes.

Methods

A multicenter, non-interventional, cross-sectional study will be conducted with patients diagnosed with RRMS (2017 McDonald criteria) and a disease duration ≤ 3 years (MS-ONSET study).

Demographic characteristics, clinical and imaging outcomes will be collected, including disability (Expanded Disability Status Scale), cognition (Symbol Digit Modalities Test), and magnetic resonance imaging findings. Additional outcomes from the patient´s perspective will be collected, including symptoms severity (SymptoMScreen), mobility (NeuroQol Upper Extremity and 12-item Multiple Sclerosis Walking Scale), health-related quality of life (29-item Multiple Sclerosis Impact Scale), fatigue (5-item Modified Fatigue Impact Scale), mood and anxiety (Hospital Anxiety and Depression Scale), cognition (5-item Perceived Deficit Questionnaire), perception of illness and stigma (Brief Illness Perception Questionnaire and Stigma Scale for Chronic Illness), coping (General Self-Efficacy Scale and Brief Cope), hopelessness (State-Trait Hopelessness Scale), experience of prognosis communication (ad-hoc questionnaire and Miller Behavioral Style Scale), and work-related difficulties and productivity (23-item Multiple Sclerosis Work Difficulties Questionnaire and Valuation of Lost Productivity). Participants will answer questions regarding the management of eight simulated MS case-scenarios based on clinical and radiological disease activity (treatment preferences). They will also complete a survey-experiment based on behavioral economics paradigms to assess risk preferences.

Results

Patient recruitment will begin in June 2020 with a planned total sample of 189 patients and 15 MS units throughout Spain.

Conclusions

The study results are expected to provide meaningful insights into the effect of patients´ perceived seriousness of MS at an early stage. A better understanding of patients´ experience may facilitate shared-decision making and foster the development of specific therapeutic planning in clinical practice.

Collapse
Patient-Reported Outcomes and Quality of Life Poster Presentation

P1050 - Quantifying the patient´s perspective in neuromyelitis optica spectrum disorders: Design of a multicenter, non-interventional study (ID 222)

Abstract

Background

Patients with neuromyelitis optica spectrum disorders (NMOSD) experience a spectrum of symptoms negatively impacting on daily living and quality of life. The systematic assessment of patient perspectives has the capacity to provide crucial clinical information that could otherwise be lost when relying on clinical evaluation alone. However, the patient experience living with NMOSD is limited, in particular implementing standardized patient-reported outcomes (PROs).

Objectives

The primary objective of this study protocol is to assess the health-related quality of life and well-being of NMOSD patients.

Methods

A multicenter, non-interventional, cross-sectional study will be conducted with patients diagnosed with NMOSD (2015 Wingerchuk criteria) (PERSPECTIVES-NMO Study). Primary outcomes measures will be the 29-item Multiple Sclerosis Impact Scale and the Satisfaction with Life Scale. Demographic characteristics, clinical and imaging outcomes will be collected, including the number and type of attacks, antibody status, Expanded Disability Status Scale score, Nine-Hole Peg Test, Timed 25-Foot Walk, and Magnetic Resonance Imaging findings. Cognition will be evaluated using the Rao Brief Repeatable Neuropsychological Battery. Additional outcomes from the patient´s perspective (PROs) will be collected, including symptoms severity (SymptoMScreen questionnaire), fatigue (Fatigue Impact Scale for Daily Use), pain (MOS Pain Effects Scale), mood (Beck Depression Inventory-Fast Screen), perception of stigma (8-item Stigma Scale for Chronic Illness), and work-related difficulties (23-item Multiple Sclerosis Work Difficulties Questionnaire).

Results

Patient recruitment began in December 2019 with a planned total sample of 70 patients. The study is currently ongoing.

Conclusions

The study results are expected to provide meaningful insights into the clinical burden of disease. A better understanding of patient experiences may foster the development of patient-centered specific plans and more targeted rehabilitation in clinical practice.

Collapse